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Abstract
Introduction: Ghrelin is a polypeptide hormone secreted mainly by the stomach cells, stimulating food intake and growth hormone
release. Decreased plasma ghrelin concentration was found in obese subjects. Clinical and experimental data suggest that ghrelin also
exerts a blood pressure lowering property. The influence of antihypertensive medication on plasma ghrelin concentration has not been
studied, yet.
Material and methods: Plasma ghrelin concentration was estimated in 52 hypertensive obese (HA + O), 14 normotensive obese (O), and
15 lean healthy subjects in the fasting state, and after ingestion of a standard meal. HA + O patients were randomly allocated into 4 groups
treated alternatively with: cilazapril, bisoprolol, amlodipine, or indapamide. After 6 weeks of antihypertensive monotherapy, the asses-
sments were repeated.
Results: Similar fasting [HA + O — 780 (676–960) pg/ml; O — 751 (619–899) pg/ml] and postprandial plasma ghrelin concentrations were
found in hypertensive and normotensive obese subjects. Plasma ghrelin concentrations in lean healthy subjects were significantly higher
(987 (765–1366) pg/ml) in comparison to O and HA + O. Treatment with cilazapril was followed by a 28.0% increase of plasma ghrelin
concentration (p = 0.04), while with bisoprolol, a 18.9% decrease (p = 0.01). No significant changes of ghrelinaemia were observed in HA
+ O treated with amlodipine or indapamide. No significant correlation between blood pressure and plasma ghrelin concentration before
the therapy and their changes after 6 weeks of medication were found.
Conclusions:
1. Our data do not support the major role of ghrelin in blood pressure regulation in obesity.
2. An increase of plasma ghrelin concentration after treatment with cilazapril was observed.
(Pol J Endocrinol 2010; 61 (1): 21–27)
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Streszczenie
Wstęp: Grelina jest hormonem polipeptydowym wydzielanym głównie przez komórki ściany żołądka. W warunkach fizjologicznych
grelina zwiększa łaknienie i wydzielanie hormonu wzrostu. U osób otyłych stwierdzono obniżone stężenie greliny w osoczu. W bada-
niach doświadczalnych i klinicznych wykazano, że grelina przyczynia się do obniżenia ciśnienia tętniczego. Jak dotąd nie przeprowadzo-
no jednak badań nad wpływem leków przeciwnadciśnieniowych na grelinemię.
Materiał i metody: U 52 otyłych chorych z nadciśnieniem tętniczym (HA + O), 14 otyłych chorych z prawidłowym ciśnieniem tętniczym
(O) i 15 osób zdrowych z prawidłową masą ciała oznaczono stężenie greliny w osoczu na czczo, jak również po podaniu standardowego
posiłku. Następnie chorzy HA + O zostali w sposób losowy przydzieleni do jednej z czterech grup leczonych przez 6 tygodni odpowied-
nio: cilazaprilem, bisoprololem, amlodipiną lub indapamidem. Po tym okresie leczenia powtórzono oznaczenia grelinemii.
Wyniki: Nie stwierdzono różnic grelinemii zarówno na czczo [HA + O — 780 (676–960) pg/ml; O — 751 (619–899) pg/ml], jak i po podaniu
standardowego posiłku pomiędzy HA + O i O. Stężenie greliny w osoczu było znamiennie wyższe u osób zdrowych z prawidłową masą
ciała (987 [765–1366] pg/ml) w porównaniu z O oraz HA + O. U HA + O leczenie cilazaprilem spowodowało wzrost o 28,0% (p = 0,04),
a leczenie bisoprololem zmniejszenie grelinemii o 18,9% (p = 0,01). Podawanie amlodipiny lub indapamidu nie wpływało istotnie na
stężenie greliny w osoczu. Nie stwierdzono występowania korelacji pomiędzy ciśnieniem tętniczym a grelinemią lub zmianami grelinemii
po 6 tygodniach leczenia.
Wnioski:
1. Uzyskane wyniki nie potwierdzają istotnej roli greliny w regulacji ciśnienia tętniczego u osób otyłych.
2. Leczenie cilazaprilem przyczynia się do wzrostu grelinemii.
(Endokrynol Pol 2010; 61 (1): 21–27)
Słowa kluczowe: grelina, otyłość, nadciśnienie tętnicze, cilazapril, leczenie przeciwnadciśnieniowe
The study was carried out as a research project supported by a Grant of the Medical University of Silesia (KNW-1-019/09)
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Introduction
Ghrelin is a 28-aminoacid peptide secreted mainly by
the stomach cells [1]. The highest plasma ghrelin con-
centration is usually detected in the fasting state [2, 3].
The decrease of plasma ghrelin concentration observed
after feeding is not related to gastric distension but ra-
ther to the stimulation of the cholinergic nervous sys-
tem via the vagus nerve, glucose absorption, and pro-
bably insulin release [4–7]. Under physiological condi-
tions, ghrelin stimulates growth hormone release and
appetite via neuropeptide Y and agouti-related protein
expressing neurons in hypothalamic nucleus arcuatus
[4, 8–10]. In obese subjects, plasma ghrelin concentra-
tions are significantly lower than in non-obese subjects
[11]. Weight loss in severely obese patients after lapa-
roscopic adjustable gastric banding (LAGB) is accom-
panied by an increase of plasma ghrelin concentration
[12, 13]. Moreover, a negative correlation between BMI
and plasma ghrelin concentration was confirmed in
some clinical studies [14–16].
The results obtained in the experimental studies
suggest that ghrelin also affects the function and struc-
ture of the cardiovascular system. Ghrelin decreases
blood pressure. Both central and peripheral mechani-
sms may participate in the vascular relaxation induced
by ghrelin infusion. The microinjection of ghrelin into
the nucleus of the solitary tract suppresses sympathetic
nerve activity and decreases blood pressure and heart
rate in rats [17, 18]. Ghrelin is also a potent endothe-
lium-dependent and endothelium-independent vaso-
dilator [19, 20]. Ghrelin improves endothelial function
by increasing endothelial nitric oxide synthesis [19].
Ghrelin is not only involved in blood pressure regula-
tion but also prevents vascular wall injury. It was shown
that ghrelin diminishes vascular oxidative stress by in-
hibition of NAD(P)H oxidases, and attenuates vascular
calcification [21, 22].
In humans it has been reported that low plasma
ghrelin concentration is associated with higher preva-
lence of arterial hypertension [23]. In addition, some
authors have found a significant negative correlation
between blood pressure and plasma ghrelin concentra-
tion [14, 24]. Nagaya et al. found that intravenous in-
jection of ghrelin decreased mean arterial pressure by
12 mm Hg, without any significant changes in heart rate
[25]. A similar haemodynamic effect was recently de-
monstrated with synthetic ghrelin receptor agonist [26].
The aim of this study was to assess plasma ghrelin
concentrations in normotensive and hypertensive obe-
se subjects. As the influence of antihypertensive medi-
cation on ghrelin release has not yet been studied, we
aimed in this single-centre, prospective, open label stu-
dy to assess the influence of 6 weeks of monotherapy
with cilazapril, bisoprolol, amlodipine, or indapamide
on plasma ghrelin concentrations in obese patients with
arterial hypertension.
Material and methods
Patients
Fifty-two obese (BMI ≥ 30 kg/m2) patients with arterial
hypertension (HA + O), 14 normotensive obese (O) and
15 lean (BMI £ 25.0 kg/m2) healthy subjects (HS) were
enrolled into this study after giving informed consent.
The patients’ characteristics are presented in Table I.
Only previously untreated patients with recently dia-
gnosed mild to moderate arterial hypertension (blood
pressure higher than or equal to 140/90 mm Hg but lo-
wer than 180/110 mm Hg) were enrolled into the HA + O
group. The exclusion criteria were as follows: seconda-
ry hypertension, chronic kidney or liver disease, dia-
betes mellitus, gout, ischaemic heart disease, neopla-
sms, or infections. Secondary forms of hypertension
were excluded based on careful clinical and biochemi-
cal examination.
Study protocol
In all subjects, blood samples for the estimation of pla-
sma ghrelin concentration were taken in the morning
in the fasting state, and additionally 30, 60, and 120 mi-
nutes after the ingestion of a standard meal consisting
of 250 ml of milk, 100 ml of grapefruit juice, 40 g of corn-
flakes, and 5 g of sugar. In addition, serum glucose, cho-
lesterol (total and HDL fraction), triglycerides, uric acid,
creatinine, and plasma insulin concentrations were es-
timated before ingestion of the standard meal. Blood
pressure was measured with a mercury sphygmoma-
nometer with an accuracy of 2 mm Hg. Obese patients
with arterial hypertension were randomly allocated into
one of four groups treated either with: angiotensin co-
nverting enzyme inhibitor — cilazapril, b-adrenergic
receptor antagonist — bisoprolol, calcium channel an-
tagonist — amlodipine, or tiazide-like diuretic — inda-
pamide. Each group consisted of 13 patients. The initial
doses of the above-mentioned antihypertensive agents
were as follows: 2.5 mg of amlodipine, bisoprolol, or
indapamide and 1.25 mg of cilazapril. Blood pressure
and heart rate were measured in the outpatient clinic
every 2 weeks. When the blood pressure was higher
than 140/90 mm Hg after 4 weeks of study, the dose of
each drug, except indapamide, was doubled. After
6 weeks of treatment, all the above-mentioned measu-
rements were repeated in fasting state and after the stan-
dard meal. The study protocol was approved by the
Local Ethical Committee.
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Biochemical examinations
Plasma samples for estimation of ghrelin and insulin
were frozen and stored at –30°C until the time of me-
asurement. Plasma ghrelin concentration was assessed
by RIA method using kits from Linco Research Inc.,
USA. The intra- and interassay coefficients of variations
were 4.4–10.0 and 14.7–16.7%, respectively. Plasma in-
sulin concentration was estimated by electrochemilu-
minescence method using Elecsys kits (Roche Diagno-
stics GmbH, Mannheim, Germany). Other parameters
were assessed by routine laboratory methods. Home-
ostasis model assessment insulin resistance index
(HOMA-IR) was calculated according to the formula:
fasting plasma glucose concentration [mg/dl] × fasting
plasma insulin concentration [mU/ml] /405. Glomerular
filtration rate (eGFR) was calculated as the endogenous
creatinine clearance, according to the formula by Cock-
croft and Gault: eGFR = (140 — Age [years]) × body
mass [kg] × 1 (for males) or 0.85 (for females)/72 × se-
rum creatinine concentration [mg/dl] [27].
Measurement of body composition by DEXA
Body composition was measured by dual-energy X-ray
absorptiometry (DEXA) using a Lunar DPX-L scanner
(Lunar Radiation Corporation, Madison, WI, USA).
Measurements were performed once, in a supine posi-
tion, before meals. This method allowed the assessment
the total fat mass (TFM) and fat mass of the trunk.
Statistical analysis
All analyses were performed using Statistica software
version 7.0 (StatSoft Inc.). Non-parametrical tests were
applied: the c2 and the Mann-Whitney U tests, to com-
pare the analysed groups, and the Wilcoxon test for
analysis of subsequent measurements. The correlation
coefficient was calculated according to the Spearman
correlation test. The first multiple regression analysis
included all patients was performed for plasma ghrelin
concentration as a dependent variable and BMI, systo-
lic or diastolic BP, age, HOMA-IR, and eGFR as indepen-
dent variables. The second multiple regression analysis
focused only on patients within the HA + O group, inclu-
ding D of plasma ghrelin concentration as a dependent
variable, and change of systolic or diastolic blood pressure
and D of HOMA-R as independent variables.
Data are presented as median values and interquar-
tile range (for comparison of analysed groups) or mean
values and 95% confidence intervals (for evaluation
changes in time within the same group).
Results
Both normotensive and hypertensive obese patients
were characterised by significantly lower plasma ghre-
lin concentrations than lean healthy subjects (Table I,
Fig. 1). Obese hypertensive and obese normotensive
patients did not differ with respect to plasma ghrelin
concentrations (Table I, Fig. 1). After ingestion of the
standard meal, a significant decline of plasma ghrelin
concentration was observed in all the examined gro-
ups. The lowest ghrelin concentrations were observed
60 minutes after ingestion of the meal (Fig. 1).
Significantly higher plasma ghrelin concentrations
were observed in obese hypertensive females than in
males [900 (779–1052) v. 743 (656–854) pg/ml, respecti-
vely; p = 0.013]. This difference persisted after adjust-
ment for BMI (923 v. 782 pg/ml, respectively).
As expected, obese subjects were characterised by
higher plasma insulin concentration and HOMA-IR
values (the highest in obese hypertensive patients). Se-
rum triglycerides and uric acid levels were also higher
in obese than in lean subjects (Table I).
In all examined subjects, in univariate analysis, signi-
ficant negative correlations were found between plasma
ghrelin concentration and BMI (r = –0.227; p = 0.04),
waist/hip ratio (r = –0.425; p < 0.001), eGFR (r = –0.231;
p = 0.04), plasma concentrations of glucose (r = –0.231;
p = 0.04), insulin (r = –0.436, p < 0.001), or HOMA-IR
(r = –0.454; p < 0.001). Surprisingly, we did not find
any significant correlation between plasma ghrelin con-
centration and total fat mass, trunk fat mass, and body
fat content. In a similar analysis restricted only to obese
hypertensive patients, similar correlations were obse-
rved between plasma ghrelin concentration and waist/
/hip ratio (r = –0.314; p = 0.02), and plasma insulin con-
centration (r = –0.436, p = 0.001) and HOMA-IR
(r = –0.444; p = 0.001). Finally, no significant correlation
between BMI, eGFR, and plasma glucose was found.
The univariate analysis of all examined subjects and
only hypertensive obese patients separately did not re-
veal any significant correlation between plasma ghre-
lin concentration and systolic (r = –0.122; p = 0.28 and
r = –0.03; p = 0.98, respectively) and diastolic (r = –0.140;
p = 0.21 and r = –0.08; p = 0.55, respectively) blood
pressure values.
The stepwise multiple regression analysis confirmed
the lack of contribution of both systolic and diastolic
blood pressure to ghrelinaemia. Only HOMA-IR (b =
= –0.411; p < 0.001) and eGFR (b = –0.198; p = 0.05)
significantly contributed to plasma ghrelin variability
(r2 = 0.23).
Treatment with cilazapril, bisoprolol, amlodipine,
and indapamide for 6 weeks was followed by a similar
reduction of systolic and diastolic blood pressure (Ta-
ble II). Treatment with cilazapril caused a significant
28.0% increase, while with bisoprolol, a 18.9% decrease
of plasma ghrelin concentration was observed (Fig. 2).
No significant changes of ghrelinaemia were observed
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Table I. Clinical and biochemical characteristics of the studied groups of patients (median values and interquartile range)
Tabela I. Kliniczna i biochemiczna charakterystyka badanych grup pacjentów (mediany i zakresy miedzykwartylowe)
Obese hypertensive Obese normotensive Healthy subjects
(n = 52) (n = 14) (n = 15)
Age (years) 42 (36–52) 42 (38–48) 39 (36–46)
Males/females 32/20 7/7 6/9
BMI [kg/m2] 33.2 (31.2–36.0) ### 32.1 (30.9–32.8) ### 22.4 (21.6–24.0)
Systolic BP [mm Hg] 155 (149–160) *** ### 123 (115–130) 120 (110–120)
Diastolic BP [mm Hg] 98 (95–100) *** ## 80 (80–85) # 75 (70–80)
Total Fat Mass [kg] 35.5 (27.9–41.5) ### 34.1 (29.8–39.7) ### 17.9 (15.5–21.4)
Trunk Fat Mass [kg] 18.5 (15.3–19.9) ### 19.3 (17.0–21.0) ### 8.6 (6.7–10.0)
Body Fat Content (%) 33.4 (28.6–44.5) ## 34.8 (30.4–46.6) ## 28.7 (23.8–32.5)
WHR 0.96 (0.86–1.00) ### 0.95 (0.88–1.00) ### 0.79 (0.77–0.84)
Creatinine [mg/dl] 1.13 (0.98–1.26) *** # 0.87 (0.81–1.07) 0.92 (0.80–1.15)
eGFR [ml/min] 113 (92–129) * ## 135 (108–136) ### 95 (75–102)
Glucose [mg/dl] 104 (96–116) 91 (81–119) 86 (81–101)
Cholesterol total [mg/dl] 224 (200–258) 239 (199–276) 217 (166–246)
Cholesterol HDL [mg/dl] 43 (34–60) 45 (40–51) 54 (48–69)
Cholesterol non-HDL [mg/dl] 179 (153–214) 192 (148–220) 152 (107–198)
Triglycerides [mg/dl] 158 (118–223) ### 139 (124–206) # 88 (75–141)
Uric acid [mg/dl] 5.27 (4.30–6.24) 5.30 (4.80–5.60) ## 3.95 (3.30–5.20)
Ghrelin [pg/ml] 780 (676–960) ## 751 (619–899) # 987 (765–1366)
Insulin [mU/ml] 12.3 (8.8–16.1) * # 8.7 (6.3–12.9) ### 4.6 (3.4–5.2)
HOMA-IR 2.96 (2.17–4.46) * # 1.87 (1.38–3.05) ### 1.02 (0.72–1.23)
Statistical significance v. obese normotensive * p < 0.05; ** p < 0.01; ***p < 0.001
Statistical significance v. healthy subjects # p < 0.05; ##p < 0.01; ### p < 0.001
BMI — body mass index, WHR — waist to hip ratio, HOMA-IR — homeostasis model assessment insulin resistance index, eGFR — estimated
glomerular filtration rate
Figure 1. Baseline plasma ghrelin concentration in obese normotensive subjects (n = 14), obese patients with arterial hypertension
(n = 52), and lean healthy subjects (n = 15) in fasting state before and after ingestion of the standard meal. Statistical significance
v. healthy subjects * p < 0.05; ** p < 0.01. Statistical significance v. before meal # p < 0.05; ## p < 0.01; ### p < 0.001
Rycina 1. Wyjściowe stężenie greliny w osoczu u otyłych osób z prawidłowym ciśnieniem tętniczym (n = 14), u otyłych osób
z nadciśnieniem tętniczym (n = 52) i u zdrowych, szczupłych osób (n = 15) oznaczone na czczo przed posiłkiem oraz po spożyciu
standardowego posiłku. Istotność statystyczna v. osoby zdrowe *p < 0,05; **p < 0,01. Istotność statystyczna v. pomiar przed posiłkiem
#p < 0,05; ##p < 0,01: ###p < 0,001
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Table II. The influence of antihypertensive treatment on the systolic and diastolic blood pressure, insulin resistance (HOMA-IR),
and plasma ghrelin concentration in obese hypertensive patients treated for 6 weeks with cilazapril, bisoprolol, amlodipine, or
indapamide (mean values and 95% confidence intervals)
Tabela II. Wpływ terapii przeciwnadciśnieniowej na ciśnienie skurczowe i rozkurczowe, insulinooporność (HOMA-IR) oraz
stężenie greliny w osoczu u otyłych osób z nadciśnieniem tętniczym leczonych przez 6 tygodni cilazaprilem, bisoprololem,
amlodipiną lub indapamidem (średnie i 95% przedziały ufności)
Cilazapril Bisoprolol Amlodipine Indapamide
(n = 13) (n = 13) (n = 13) (n = 13)
Initial systolic BP 152 156 157 151
[mm Hg] (147–157) (152–159) (152–162) (148–155)
Changes of systolic BP –24 –32 –28 –25
[mm Hg] ([–29]–[–18]) ([–37]–[–25]) ([–35]–[–22]) ([–31]–[–20])
Initial diastolic BP 99 97 100 95
[mm Hg] (97–101) (96–100) (98–103) (93–96)
Changes of diastolic BP –20 –20 –22 ** –16
[mm Hg] ([–24]–[–16]) ([–25]–[–16]) ([–25]–[–18]) ([–19]–[–14])
Initial HOMA-IR 3.99 3.24 2.97 2.99
(2.78–5.21) (2.22–4.27)  (2.29–3.64) (2.43–3.56)
Changes of HOMA-IR –0.26 –0.15 –0.25 0.51
([–1.92]–1.41) ([–0.93]–0.62)  ([–1.00]–0.51)  ([–0.62]–1.65)
Initial ghrelin 725 990* 860 751
[pg/ml] (657–795) (767–1100) (762–903) (674–885)
Changes of ghrelin 171 –204** 21 51
[pg/ml] (25–318) ([–366]–[–42]) ([–72]–115) ([–70]–173)
Statistical significance v. Indapamide * p < 0.05; ** p < 0.01
Figure 2. Fasting (0) and 30, 60, and 120 minutes after ingestion of the standard meal plasma ghrelin concentration in obese hypertensive
patients before (continuous lines and filled diamonds) and 6 weeks after (interrupted lines and empty squares) initiation of the
antihypertensive medication with cilazapril, bisoprolol, amlodipine, and indapamide, respectively (means and 95% CI, statistical
significance, and p value v. pre-treatment values)
Rycina 2. Stężenie greliny w osoczu na czczo (0) oraz 30, 60 i 120 minut po spożyciu standardowego posiłku u otyłych osób z nadciśnieniem
tętniczym przed (linia ciagła, czarne romby) i 6 tygodni po (linia przerywana, białe kwadraty) rozpoczęciu leczenia przeciwnadciśnieniowego
cilazaprilem, bisoprololem, amlodipiną lub indapamidem (średnie i 95% przedziały ufności, istotność statystyczna oraz p dla danej
wartości v. wartość przed leczeniem)
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Figure 3. Relationship between changes of homeostasis model
assessment insulin resistance index (HOMA-IR) and changes of
plasma ghrelin concentration after 6 weeks of antihypertensive
treatment in obese humans (n = 52) (irrespective of the type of drug)
Rycina 3. Zależność między zmianami wartości wskaźnika
insulinooporności HOMA-IR a zmianami stężenia greliny
w osoczu po 6 tygodniach leczenia przeciwnadciśnieniowego u osób
otyłych (n = 52) (niezależnie od rodzaju leku)
in patients treated with amlodipine or indapamide (Fig. 2).
In addition, changes in HOMA-IR were not significant
(Table II). The most pronounced tendency to increase
HOMA-IR was observed in patients treated with inda-
pamide (Table II).
After 6 weeks of antihypertensive medication, no
relationship was found between changes of blood pres-
sure and changes of plasma ghrelin concentration. In
contrast, a significant negative correlation was noticed
between HOMA-IR changes and changes in plasma
ghrelin concentration (r = –0.303; p = 0.03) (Fig. 3). Ste-
pwise multiple regression analysis of factors potential-
ly influencing changes of plasma ghrelin concentration
(r2 = 0.11) documented only the contribution of HOMA-IR
changes (b = –0.331; p = 0.017).
Discussion
The results of the present study do not support the hy-
pothesis regarding the importance of the role of low
plasma ghrelin concentration in the pathogenesis of ele-
vated blood pressure in obese humans. We found simi-
lar plasma ghrelin concentrations in obese subjects suf-
fering or not suffering from arterial hypertension. The-
re was also no significant relationship between blood
pressure and plasma ghrelin concentration and chan-
ges of blood pressure during the treatment and ghreli-
naemia, respectively. A strong methodological point of
our study is that our hypertensive patients did not pre-
viously receive any antihypertensive drugs.
One clinical study which clearly demonstrated an
association between blood pressure and plasma ghre-
lin concentration was the substudy of OPERA (Oulu
Project Elucidating Risk of Atherosclerosis) [23]. Howe-
ver, in this study there was only a 5 mm Hg difference
of systolic and 2 mm Hg of diastolic blood pressure be-
tween extreme ghrelin quartiles [23]. In addition, a si-
gnificant negative correlation between blood pressure
and plasma ghrelin concentration was reported [14, 24].
In contrast to the above-mentioned studies, we did not
find such a correlation. The cause of these discrepan-
cies is unclear. Of note, we found similar concentrations
of plasma ghrelin in hypertensive and normotensive
obese humans. Therefore, the importance of ghrelin in
obesity-related hypertension is not crucial.
In the interventional part of this study, a significant
increase of plasma ghrelin concentration after treatment
with cilazapril was noticed. However, monotherapy
with indapamide or amlodipine did not influence pla-
sma ghrelin concentration. Therefore, changes of pla-
sma ghrelin concentration were not directly related to
the blood pressure lowering effect.
There are several experimental and clinical observa-
tions suggesting that plasma ghrelin concentration is
related to the degree of insulin resistance [5, 24, 28]. In
the present study, in the entire group, a significant ne-
gative correlation was noticed between HOMA-IR
changes and changes in plasma ghrelin concentration
(Fig. 3). The significant increase of plasma ghrelin con-
centration after treatment with cilazapril, and the de-
crease after bisoprolol therapy, may be explained, ho-
wever, only partially, by changes in insulin sensitivity
as no significant changes in mean HOMA-IR in any of
the groups were noticed.
What is the possible clinical implication of the incre-
ase of plasma ghrelin concentration after treatment with
cilazapril? The beneficial cardiovascular effect of an-
giotensin-converting enzyme inhibitors is claimed to
exceed the blood pressure lowering mechanism [29]. In
experimental models it has been shown that ghrelin di-
minishes vascular oxidative stress, reduces inflamma-
tory endothelial response, attenuates vascular calcifi-
cation, and prevents left ventricular hypertrophy [21,
22, 30, 31]. We can only speculate that the increase in
plasma ghrelin concentration after cilazapril treatment
leads to cardio- and vasculo-protection. Such an attracti-
ve hypothesis concerning the novel mechanisms of an-
giotensin-converting enzyme inhibitor action needs
further studies.
Contrary to cilazapril, bisoprolol therapy reduces
plasma ghrelin concentrations. This decrease could po-
tentially have orexogenic effect. However, the meta-
analysis by Sharma et al. showed that treatment with
b-adrenergic antagonists led to weight gain [32]. The
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relationship between b-adrenergic antagonists and re-
gulation of appetite is much more complex. Beta-ad-
renergic antagonists also decrease plasma leptin con-
centrations, and through this mechanism may stimula-
te appetite [33]. Both ghrelin and leptin regulate satiety
by modulation of neuropeptide Y release from the neu-
rons located in the arcuate nucleus [9, 34]. As these pep-
tides have the opposite influence, the improvement
of appetite by b-adrenergic antagonists may be only
very mild.
There are several limitations of our study. We did
not measure plasma catecholamines and angiotensin II
concentrations. Thus, we could not prove or deny the
concept concerning the interrelation between these two
strong vasoconstrictive agents and plasma ghrelin con-
centrations. Moreover, we only estimated insulin sen-
sitivity by calculation of HOMA-IR indexes, instead of
the more accurate euglycaemic-hyperinsulinemic glu-
cose clamp technique. Therefore, we are not able to exc-
lude minor changes in insulin sensitivity after antihy-
pertensive treatment.
Conclusions
The results of our study do not confirm the major role
of ghrelin in blood pressure regulation in obesity. The
increase of plasma ghrelin concentration after treatment
with cilazapril may be a novel, potentially cardiopro-
tective mechanism of angiotensin-converting enzyme
inhibitor action.
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